United States Patent 10,198,218: Scope, Claim Boundaries, and US Patent Landscape for SC Buprenorphine (PLGA/NMP) for Opioid Dependence
US Patent 10,198,218 is a method-of-treatment patent focused on subcutaneous administration of a buprenorphine free-base formulation that includes PLGA (poly(lactide-co-glycolide)) and N-methyl-2-pyrrolidone (NMP). The claims define the invention through (i) composition weight-percent ranges, (ii) PLGA micro/grade parameters (lactide:glycolide ratios and molecular weight), and (iii) dosing frequency / depot duration (28 days, monthly, and two-month intervals, plus sustained release for at least 28/45/60 days).
This patent is designed to capture a narrow formulation space (buprenorphine free base in a PLGA/NMP injectable that forms an implant in situ) and a narrow use pattern (opioid dependence dosing by subcutaneous injection at specified intervals and sustained-release durations).
What do the claims actually cover? (Core claim elements)
1) What is the method doing?
The claims require a method for treating opioid dependence by administering to a subject/patient:
- Route: subcutaneous injection (all independent method claim formulations require SC administration)
- Therapeutic goal: treat opioid dependence
- Dosing interval: every 28 days, once per month, or once every two months (claims split across different timing sets)
- Delivery mode (functional): in some claims, the composition is transformed in situ into an implant by body fluid contact
- Sustained release duration (functional): at least 28 days, 45 days, and/or 60 days depending on the dependent claim
2) What must be in the formulation?
The independent claim 1 and its dependent claims require a pharmaceutical composition with all three components:
- Buprenorphine free base
- PLGA (poly(lactide-co-glycolide) copolymer)
- N-methyl-2-pyrrolidone (NMP)
The claims repeatedly use wt % ranges and specify tight points (e.g., ~18 wt % buprenorphine free base; ~32 wt % PLGA; ~50 wt % NMP).
3) What parameters constrain PLGA identity?
The PLGA is constrained by:
- Lactide:glycolide ratio: claim 9 lists multiple ratios (50/50 through 95/5); claim 10 selects 50/50
- Molecular weight range: claim 13 (5,000 to 40,000 Daltons); claim 14 (10,000 to 20,000)
- End group / chemistry: claim 24 specifies carboxy terminal group plus 10,000 to 20,000 and 50/50 ratio
Together, these constraints are meant to avoid reading on arbitrary PLGA grades.
Where are the “hard boundaries” of infringement risk?
A. Component identity and physical form
- Buprenorphine must be free base (claims state “buprenorphine free base,” not salts)
- NMP must be included as an ingredient (wt % ranges and presence are required)
- PLGA is required as the polymer matrix (and constrained as noted above)
Practical implication for landscape: any design-around that removes NMP, uses a different solvent system, replaces PLGA with another polymer, or uses a different buprenorphine form (salt vs free base) should fall outside the literal claim scope.
B. Composition wt % ranges are “all-component” gating
Claim 1 requires all three wt % ranges simultaneously:
- Buprenorphine free base: 10 wt % to ~50 wt %
- PLGA: 5 wt % to ~70 wt %
- NMP: no explicit wt % range in claim 1, but later claims impose ranges including 10 to ~70 wt % NMP (claim 11) and specific ~50 wt % NMP (claim 12/15 and others).
So, even if a competitor matches buprenorphine and PLGA but omits NMP or keeps NMP outside later dependent-claim ranges, risk may shift from full literal coverage to partial or no coverage depending on which claim the patentee asserts.
C. Dosing interval and sustained-release claims create timing-based coverage
Claims add timing and functional depot duration:
- Claim 2 / 3: once every 28 days / “once per month”
- Claims 17 to 19: sustained release for at least 28 days, 45 days, 60 days
In parallel, claims 26 and 31 create coverage for once every two months.
Practical implication: a product that uses the same composition but doses at a cadence outside the claimed intervals could avoid dependent-claim traction, though independent claim 1 is not expressly tied to the interval. This makes claim selection crucial in enforcement.
Claim chart view: independent claims vs key dependent “narrowers”
Independent claim 1
Method for opioid dependence with:
- SC administration of a composition comprising:
- 10–~50 wt % buprenorphine free base
- 5–~70 wt % PLGA
- NMP
- to treat opioid dependence
Dependent claim set (main narrowers)
Key dependent features include:
Independent claim 15 (fixed composition)
Claim 15 is structurally specific:
- SC injection composition of:
- ~18 wt % buprenorphine free base
- ~32 wt % PLGA
- ~50 wt % NMP
Then it adds:
- Claim 16: in situ transformed into implant by contact with body fluid
- Claim 17-19: sustained release durations (28/45/60 days)
Independent claim 26 (two-month dosing plus fixed composition)
Claim 26:
- SC administration once every two months
- composition:
- ~18 wt % buprenorphine free base
- ~32 wt % PLGA
- ~50 wt % NMP
Then dependent narrowers repeat PLGA ratio (50/50), molecular weight windows, carboxy terminal group, and buprenorphine mass range.
Claim 31 (two-month dosing plus broad buprenorphine/PLGA wt ranges)
Claim 31:
- once every two months
- composition ranges:
- 10–~50 wt % buprenorphine free base
- 5–~70 wt % PLGA
- NMP
Then dependent claims 32–35 narrow those ranges and specify PLGA molecular weight.
What is the “product-like” embodiment implied by the claim set?
The claims converge on a single “center-of-gravity” formulation:
- ~18 wt % buprenorphine free base
- ~32 wt % PLGA
- ~50 wt % NMP
- SC injection
- optionally: in situ implant formation
- sustained release at least 28 days and up to 60 days
- dosing schedules include monthly and every two months claim pathways
- buprenorphine dose loading tied to total mass and volume in some dependent claims:
- Claim 20: ~3 mg to ~300 mg buprenorphine free base; composition volume ~0.5 mL
- Claim 21: ~9 mg to ~900 mg; volume ~1.5 mL
- Claim 25: buprenorphine composition ~3–~300 mg
These constraints suggest the patent is written to cover multiple strength presentations (0.5 mL and 1.5 mL volumes) within the same wt % formulation architecture.
Where does the claim scope overlap with the broader US buprenorphine LAI/implants landscape?
The patent sits in the intersection of:
- buprenorphine long-acting / depot products for opioid use disorder
- polymer-based depots using PLGA as a biodegradable matrix
- solvent/vehicle systems using NMP
- in situ forming implant concepts (liquid injectate forms a depot once in body fluid)
In the US, the major commercial long-acting buprenorphine trajectory is associated with long-acting injectables (LAIs) intended for opioid use disorder, including depot-forming and sustained-release formulations. Patent landscapes around those products typically cluster around:
- the drug form (free base vs salt),
- the carrier/polymer and its grade,
- the vehicle/solvent system,
- the in situ formation mechanism,
- the release profile and dosing interval.
Within that typical landscape, US 10,198,218 is composition-and-interval specific: the claims repeatedly require the specific buprenorphine free base + PLGA + NMP architecture and then tighten PLGA grade and injection frequency.
Patent landscape analysis: likely risk zones for competitors (US) based on claim architecture
1) Direct-structure design risk (highest)
Products that use:
- buprenorphine free base
- PLGA (including 50/50 and molecular weights in the stated bands)
- NMP in the claimed wt % ranges
- SC injection that forms a depot/implant in situ
- monthly or two-month dosing
are at the highest literal-infringement risk. The presence of multiple claim pathways (monthly, two-month, sustained release durations, fixed wt % composition) increases the chance that an asserted claim matches the product.
2) Partial design risk (medium)
If a competitor matches the composition architecture but deviates in one axis:
- PLGA ratio outside claim 9 list or uses different lactide:glycolide
- PLGA molecular weight outside 5,000–40,000 or 10,000–20,000 or uses different end-group chemistry
- buprenorphine form (salt instead of free base)
- solvent replaces NMP
- injection frequency outside “once every 28 days / once per month / once every two months”
then enforcement leverage depends on whether the patentee targets the broader independent claim 1 (composition ranges) or narrower dependent claims (interval, wt points, sustained release minimums).
3) Polymer-vehicle substitutions (best literal avoidance)
Because the claims require NMP and PLGA together, the most direct “out” is changing:
- the polymer matrix away from PLGA, or
- the vehicle away from NMP, or
- both.
Those changes should defeat at least one required ingredient, breaking literal coverage.
4) Mechanism/implant formation (functional dependent risk)
Claims 16 and 17–19 hinge on:
- in situ transformation into an implant
- sustained release minimums
If a competitor’s formulation does not form an implant in situ and instead uses a different release mechanism (for example, pre-formed depot geometry or a non-implant release model), then those dependent claims may not be met even if composition wt % overlaps.
Scope map: claim elements that matter for freedom-to-operate
Element checklist for a potential product
A US product that wants to avoid exposure mapped to this patent should be able to demonstrate at least one of the following:
- buprenorphine is not the free base (e.g., use of salt form)
- NMP is not present or is outside claimed wt % ranges (where those ranges are asserted)
- PLGA is not used, or PLGA identity is outside the claimed grade boundaries (ratio, molecular weight, carboxy terminal group)
- dosing frequency is outside the claimed intervals, or sustained release is outside the stated minimums when dependent claims are asserted
Claim pathways that broaden or narrow enforcement
- Broadest composition structure appears in claim 1 and claim 31 (range-based buprenorphine and PLGA with NMP).
- Tightest “center” appears in claims 15 and 26 (fixed ~18/32/50 wt % architecture).
- PLGA grade is narrowed in multiple dependent claims (ratio and MW and carboxy end group).
- Release and implant-formation concepts are captured in dependent claims (16 and 17–19).
Key takeaways
- US 10,198,218 is a composition-and-dosing method patent for SC buprenorphine free-base therapy in opioid dependence using PLGA + NMP.
- The claim set concentrates on a specific formulation nucleus: ~18 wt % buprenorphine free base / ~32 wt % PLGA / ~50 wt % NMP, with PLGA grade constraints and depot formation/sustained release dependent limitations.
- Risk is highest for products that match the full architecture, including buprenorphine free base, NMP, PLGA identity (ratio and molecular weight), and SC dosing cadence (monthly or two-month intervals), plus sustained release minimums where asserted.
- The most direct literal design-around is changing at least one required axis: omit NMP, change from PLGA to another polymer, or use a non-free-base buprenorphine form.
FAQs
1) Is US 10,198,218 limited to monthly dosing only?
No. It includes “once every twenty-eight days” and “once per month” pathways, and it also contains a separate dosing pathway for once every two months.
2) Does infringement require the formulation to be transformed into an implant in situ?
Only for the specific dependent claim that includes that functional limitation. The core composition method claims focus on the SC administration of the specified formulation.
3) How central is N-methyl-2-pyrrolidone (NMP) in the claim set?
NMP is required as an ingredient in the method composition. The claim set also includes dependent wt % ranges and a specific ~50 wt % point.
4) Are the claims tied to PLGA lactide:glycolide ratio?
Yes. The patent includes dependent claims specifying multiple PLGA ratios and also a dedicated dependent claim for 50/50, plus molecular weight ranges and an end-group (carboxy terminal).
5) Does the patent cover buprenorphine dose strength in mg?
Dependent claims include buprenorphine free-base mass ranges and associated composition volume examples (e.g., ~0.5 mL and ~1.5 mL presentations), indicating coverage across multiple loading strengths within the formulation system.
References
[1] US Patent 10,198,218. Claims provided in user prompt.
